Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers

Figures & data

Figure 1. Percentage of patients achieving sc-PGA (1a), pp-PGA (1b), sPGA-G (1c) and f-PGA (1d) of 0 or 1 (clear and almost clear) at weeks 16, 28 and 52.

Abbreviation: sc-PGA: scalp-specific Physician’s Global Assessment; pp-PGA: palmoplantar PGA sPGA-G: static Physician’s Global Assessment of Genitalia; f-PGA: fingernail PGA.

Figure 2. Mean site-specific PGA of our population at baseline, week 16, week 28 and week 52.

Abbreviation: sc-PGA: scalp-specific Physician’s Global Assessment; pp-PGA: palmoplantar PGA sPGA-G: static Physician’s Global Assessment of Genitalia; f-PGA: fingernail PGA; * p-value < 0.001.

Table 1. Demographic characteristics and disease severity scores at baseline of our population.

Number of patients, N	202
Males, N (%)	133 (65.8)
Age, mean ± SD	50.43 ± 15.95
BMI, mean ± SD	27.37 ± 5.30
Disease Duration, mean ± SD	17.27 ± 14.32
PsA, N (%)	20 (9.9)
≥1 Difficult-to-treat areas, N (%)	87 (43.1)
Cardiometabolic comorbidities	72 (35.6)
Bio-Naïve, N (%)	156 (77.2)
PASI baseline, mean ± SD	14.79 ± 8.55
sc-PGA ≥4, N (%)	53 (32.1)
pp-PGA ≥4, N (%)	4 (19.1)
sPGA-G ≥ 4, N (%)	23 (31.9)
f-PGA ≥4, N (%)	13 (26)

Abbreviation: BMI: Body Mass Index; PsA: Psoriatic Arthritis; PASI: Psoriasis Area and Severity Index; sc-PGA: scalp-specific Physician’s Global Assessment; pp-PGA: palmoplantar PGA sPGA-G: static Physician’s Global Assessment of Genitalia; f-PGA: fingernail PGA.

Data availability statement

Data are available on request from the authors.